Amryt Pharma (AMYT)

Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

Diurnal (DNL)

Founded in 2004, Diurnal is a UK-based, globally-focused specialty pharma company developing high quality products for the life-long treatment of chronic endocrine conditions.

They are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).

Diurnal’s expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body’s natural hormone levels), which has yielded novel product candidates being trialled in patients prior to the submission of a marketing authorisation application.

Midatech Pharma (MTPH)

Midatech Pharma (MTPH) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines.

Driven by a team of scientists, engineers, and pharmaceutical development specialists, and led by an experienced management team, Midatech is progressing a pipeline of differentiated therapeutics in areas of high unmet need for the benefit of patients.